Your session is about to expire
← Back to Search
Combination Therapy for Non-Small Cell Lung Cancer
Study Summary
This trial will test a combination of therapies for stage IB-III non-small cell lung cancer. If successful, it could become a new standard of care for this disease.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am postmenopausal or not pregnant if premenopausal.My lung cancer diagnosis was confirmed through a lab test.My lung cancer is at a stage where surgery can completely remove it.I am fully active or can carry out light work.I agree to use birth control during the study.My lungs are strong enough for surgery.Lymph nodes in a specific area must be separate and not joined together.I am older than 18 years.My organs and bone marrow are working well.I have been checked by a lung surgeon before signing up.I have never had radiation therapy to the chest area.I understand the details of the clinical trial and can consent to participate.
- Group 1: Protocol Therapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many people are being asked to participate in this clinical trial?
"That is correct. As of February 22nd, 2022, this clinical trial was still recruiting patients that had first been posted about on October 5th, 2021. They are seeking 25 individuals from 1 medical location."
What is the history of Ipilimumab in research?
"Ipilimumab is being researched in 796 clinical trials, 86 of which are currently active. The many Phase 3 studies for Ipilimumab primarily take place in Pittsburgh, Pennsylvania; however, there are 43300 locations running these sorts of trials."
What are the conditions Ipilimumab is used to treat?
"Treatments that can be administered using Ipilimumab include anti-angiogenic therapy, malignant neoplasms, and unresectable melanoma."
Are volunteers still being sought for this experiment?
"Based on the information available on clinicaltrials.gov, it appears that this study is still recruiting patients. The trial was first posted on 10/5/2021 and was last updated on 2/22/2022. They are looking for a total of 25 participants from 1 site."
Could you explain the possible risks associated with Ipilimumab?
"While there is data supporting Ipilimumab's safety, it garnered a score of 2 because there is no evidence backing its efficacy."
Share this study with friends
Copy Link
Messenger